Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

(“Vertex” or the “Company”), a global provider of tax technology solutions, has been named a Leader in three IDC MarketScape reports: IDC MarketScape: Worldwide SaaS and Cloud-Enabled SaaS ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

The first medical treatment to use Crispr gene editing has been on the market for a year. Its complexity means few patients ...

A member of the IBD Big Cap 20, Vertex is a top stock to consider after impressive growth last year. VERX stock could present ...

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

Vertex, Inc., a leading provider of tax technology solutions, has been recognized as a Leader in three recent IDC MarketScape reports assessing SaaS and cloud-enabled tax automation software for ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Fintel reports that on January 3, 2025, Raymond James downgraded their outlook for Vertex (NasdaqGM:VERX) from Outperform to Market Perform. Analyst Price Forecast Suggests 8.59% Upside As of December ...